ArchivesMagazine - 20 May 2021Buy Shield Therapeutics as it stands on cusp of US breakthrough Iron deficiency drug Accrufer could generate hundreds of millions in revenue in the coming years 20 May 2021|Great Ideas Issue: 20 May 2021 - Page 10 < Is good news on the UK property surge now priced into housebuilders? Hill & Smith set to cash in on US infrastructure boom > Issue: 20 May 2021 - Page 10 | Contents Next: Hill & Smith set to cash in on US infrastructure boom Previous: Is good news on the UK property surge now priced into housebuilders? Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Martin Gamble Issue Contents Ask Tom Should I use a SIPP or an ISA for retirement savings? Case study Investor diary: looking for value and growth Editor's View Bitcoin’s entry into the mainstream is proving short-lived Feature US vs China – which is best for investors and where should you put your money? The case for and against share buybacks Covid-19 diagnostic firms have fallen too far given they still play a crucial role Funds The value funds vying for top dog status Great Ideas Hill & Smith set to cash in on US infrastructure boom Improving backdrop for still cheap TT Electronics Buy Shield Therapeutics as it stands on cusp of US breakthrough Bank a tidy profit on UDG as private equity swoops Investors toast Diageo’s £4.5 billion capital return Coca-Cola HBC should fizz higher on reopening Investment Trusts How to analyse property-focused investment trusts, aka REITs News UK stocks slump as inflation doubles in April This year’s UK IPOs reward investors despite Deliveroo and Alphawave flops Indian Covid strain a threat to hospitality and travel sectors Is good news on the UK property surge now priced into housebuilders? Personal Finance Protecting your pension income from inflation Russ Mould Commodities remain central to the FTSE 100